Literature DB >> 9688448

Science and pragmatism in the treatment and prevention of neutropenic infection.

J Klastersky1.   

Abstract

The following aspects of the management of patients with granulocytopenia and fever are reviewed in this article: adaptation of initial antibiotic regimens to the recent changes in the most common causative pathogens (namely a change from Gram-negative bacteria to Gram-positive bacteria and fungi); subsequent modifications of the empirically administered treatments; improvement of the host's defence by reducing the duration of neutropenia; and indications for out patient therapy of febrile episodes.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9688448     DOI: 10.1093/jac/41.suppl_4.13

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  13 in total

1.  Prophylactic application of fluoroquinolones for selective decontamination of the gut: friend or foe.

Authors:  A van Belkum; M C Vos
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-02       Impact factor: 3.267

Review 2.  The Microbiota in Hematologic Malignancies.

Authors:  Yajing Song; Bryan Himmel; Lars Öhrmalm; Peter Gyarmati
Journal:  Curr Treat Options Oncol       Date:  2020-01-11

Review 3.  Piperacillin/tazobactam: an updated review of its use in the treatment of bacterial infections.

Authors:  C M Perry; A Markham
Journal:  Drugs       Date:  1999-05       Impact factor: 9.546

4.  Microbial etiology of febrile neutropenia.

Authors:  Mudshingkar Swati; Nataraj Gita; Baveja Sujata; Jijina Farah; Mehta Preeti
Journal:  Indian J Hematol Blood Transfus       Date:  2010-09-30       Impact factor: 0.900

5.  Clinical factors predicting bacteremia in low-risk febrile neutropenia after anti-cancer chemotherapy.

Authors:  Young Eun Ha; Jae-Hoon Song; Won Ki Kang; Kyong Ran Peck; Doo Ryeon Chung; Cheol-In Kang; Mi-Kyong Joung; Eun-Jeong Joo; Kyung Mok Shon
Journal:  Support Care Cancer       Date:  2010-10-08       Impact factor: 3.603

6.  Monotherapy with intravenous followed by oral high-dose ciprofloxacin versus combination therapy with ceftazidime plus amikacin as initial empiric therapy for granulocytopenic patients with fever.

Authors:  H Giamarellou; H P Bassaris; G Petrikkos; W Busch; M Voulgarelis; A Antoniadou; E Grouzi; N Zoumbos
Journal:  Antimicrob Agents Chemother       Date:  2000-12       Impact factor: 5.191

7.  Bacterial spectrum and antimicrobial susceptibility pattern of bloodstream infections in children with febrile neutropenia: experience of single center in southeast of Turkey.

Authors:  Selda Aslan; Elvan Caglar Citak; Reyhan Yis; Suleyman Degirmenci; Dilek Arman
Journal:  Indian J Microbiol       Date:  2011-08-13       Impact factor: 2.461

8.  Causes of fever in cancer patients (prospective study over 477 episodes).

Authors:  E Toussaint; E Bahel-Ball; M Vekemans; A Georgala; L Al-Hakak; M Paesmans; M Aoun
Journal:  Support Care Cancer       Date:  2006-03-10       Impact factor: 3.603

9.  Rapid emergence of ciprofloxacin-resistant enterobacteriaceae containing multiple gentamicin resistance-associated integrons in a Dutch hospital.

Authors:  A van Belkum; W Goessens; C van der Schee; N Lemmens-den Toom; M C Vos; J Cornelissen; E Lugtenburg; S de Marie; H Verbrugh; B Löwenberg; H Endtz
Journal:  Emerg Infect Dis       Date:  2001 Sep-Oct       Impact factor: 6.883

10.  Epidemiology and outcome of bacteraemia in neutropenic patients in a single institution from 1991-2012.

Authors:  M Ortega; F Marco; A Soriano; M Almela; J A Martínez; M Rovira; J Esteve; J Mensa
Journal:  Epidemiol Infect       Date:  2014-06-30       Impact factor: 4.434

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.